SCHEMBL2968050

SCHEMBL2968050

CCc1nc2nc(O)c(-c3ccccc3)c(O)n2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
ATM Q13315 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 3/20 0.38
LMNA P02545 1/20 0.38
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
KMT2A Q03164 2/20 0.35
USP2 O75604 1/20 0.35
MAPT P10636 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ESR1 P03372 2/20 0.35
ESR2 Q92731 2/20 0.35
PDE10A Q9Y233 3/20 0.34
FABP3 P05413 1/20 0.34
FABP4 P15090 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360770 0.82 MAPT (0.41) ALDH1A1KDM4EHPGDCASP1CASP7
SCHEMBL2964669 0.78 KDM4E (0.49) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL2970170 0.77 PTGS1 (0.36) ALDH1A1KDM4EHPGDCASP1CASP7
SCHEMBL2964035 0.74 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDCASP1CASP7
SCHEMBL10408728 0.74 KDM4E (0.45) ALDH1A1KDM4EHPGDATMHSD17B10
SCHEMBL8013744 0.72 MAPT (0.32) ALDH1A1KDM4EHPGDTSHRLMNA
SCHEMBL868954 0.70 KDM4E (0.49) ALDH1A1KDM4EHPGDTSHRLMNA
SCHEMBL2979080 0.70 MAPT (0.48) ALDH1A1KDM4EHPGDLMNAKMT2A
SCHEMBL23925371 0.69 KDM4E (0.48) ALDH1A1KDM4EHPGDTSHRLMNA
SCHEMBL2964886 0.68 NPC1 (0.47) ALDH1A1KDM4EHPGDATMHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2396330-B1 FUSED PYRIMIDINES BAYER IP GMBH (DE) 2016-04-06 EP disclosed
US-8957064-B2 Fused pyrimidines BAYER INTELLECTUAL PROPERTY GMBH (US) 2015-02-17 US disclosed
US-8614218-B2 Fused bicyclic pyrimidines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-12-24 US disclosed
US-20130317002-A1 FUSED PYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2013-11-28 US disclosed
EP-2188291-B1 FUSED BICYCLIC PYRIMIDINES Bayer Pharma AG (DE) 2012-09-19 EP disclosed
EP-2396330-A1 FUSED PYRIMIDINES Bayer Pharma Aktiengesellschaft (DE) 2011-12-21 EP disclosed
WO-2010091808-A1 FUSED PYRIMIDINES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-08-19 WO disclosed
US-7776864-B2 Fused bicyclic pyrimidines BAYER SCHERING PHARMA AG (DE) 2010-08-17 US disclosed
US-20100184782-A1 FUSED BICYCLIC PYRIMIDINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2010-07-22 US disclosed
US-20090137607-A1 FUSED BICYCLIC PYRIMIDINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137607-A1 FUSED BICYCLIC PYRIMIDINES PIK3CA, TYMS, MTOR ALDH1A1 3182/4885KDM4E 3173/4885HPGD 3694/4885
US-20130317002-A1 FUSED PYRIMIDINES PIK3CA, MTOR, TYMS ALDH1A1 3442/4885KDM4E 3716/4885HPGD 1880/4885
US-20100184782-A1 FUSED BICYCLIC PYRIMIDINES PIK3CA, TYMS, MTOR ALDH1A1 3182/4885KDM4E 3173/4885HPGD 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.